Low molecular weight heparin: a practical approach in deep venous thrombosis in palliative care

低分子肝素:姑息治疗中深静脉血栓形成的实用方法

阅读:1

Abstract

INTRODUCTION: Deep vein thrombosis (DVT) is one of the many cause of pain in advance cases of carcinoma cervix. The most widely used agent for combating DVT is unfractionated heparin. AIMS: Aims of this study is to see the efficacy of the use of low molecular weight (LMW) haparin and its practical utility in palliative care settings. MATERIALS AND METHODS: Twelve cases of established DVT received enoxaparin at 40 mg/m with warfarin. RESULTS: There was 70% resolution of limb swelling in seven cases. Out of remaining four cases took two months to resolve and one case did not resolve completely. CONCLUSIONS: LMV heparin is effective in palliative care setting and also has added advantage of subcutaneous route of administration.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。